metaPreg - Metronidazole (all routes except local only) during pregnancy

Metronidazole (all routes except local only) updated on 01-29-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.10 [0.97, 1.26]	0%	9 studies	61,391	3,716	not evaluable	ROB	-
Major congenital malformations	1.15 [0.98, 1.34]	0%	6 studies	32,083	2,509	not evaluable	ROB	-
Congenital heart defects	0.92 [0.63, 1.34]	0%	3 studies	5,653	1,907	not evaluable	ROB	-
Cleft palate	0.49 [0.10, 2.52]	0%	2 studies	672	575	not evaluable	ROB	-
Limb defects	0.98 [0.68, 1.40]	0%	2 studies	4,935	1,730	not evaluable	ROB	-
Nervous system anomalies	0.66 [0.34, 1.25]	0%	2 studies	760	1,730	not evaluable	ROB	-
Respiratory system anomalies	1.07 [0.32, 3.64]	0%	2 studies	571	1,730	not evaluable	ROB	-
Club foot / Talipes equinovarus	1.26 [0.68, 2.30]	3%	2 studies	2,459	184	not evaluable	ROB	-
Ano-rectal atresia and stenosis	3.35 [1.05, 10.66]	-	1 study	160	165	not evaluable	ROB	6.16 [1.29; .]
Hydrocephaly	3.48 [1.41, 8.57]	-	1 study	278	167	not evaluable	ROB	6.42 [2.18; .]
Minor congenital malformations	-	-	0 study					-
Polydactyly	1.86 [1.03, 3.36]	-	1 study	1,266	174	not evaluable	ROB	3.12 [1.21; .]
15 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	1.32 [0.86, 2.03]	71%	5 studies	1,195	1,398	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Leukemia	1.39 [0.85, 2.27]	0%	2 studies	445	90	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine death (< 22 weeks)	1.47 [0.98, 2.21]	42%	2 studies	8,762	204	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks)	0.54 [0.18, 1.68]	0%	2 studies	13	1,526	not evaluable	ROB	-
Ectopic pregnancy	-	-	0 study					-
Elective/induced termination of pregnancy	3.41 [1.86, 6.25]	-	1 study	45	228	not evaluable	ROB	6.27 [3.12; .]
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study